Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Cong ZENG; Xu CHEN; Juan HUA; Tingting CHENG; Xia MA; Yajing XU

doi:10.16016/j.1000-5404.202108112

您当前的位置：

首页 >

文章列表页 >

Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Monographic Reports: Basic and clinical research on complications after hematopoietic stem cell transplantation | 更新时间：2026-01-09

- Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
- Journal of Third Military Medical University Vol. 43, Issue 21, Pages: 2302-2306(2021)
- 作者机构：
  
  410008 长沙，中南大学湘雅医院血液内科
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(81974002);the Translational Research Grant of National Clinical Research Center for Hematology(2021WWC02)
- DOI：10.16016/j.1000-5404.202108112
  CLC： R617;R969.4;R979.3
- Received：16 August 2021，
  
  Revised：2021-09-05，
  
  Published：15 November 2021
- 稿件说明：
移动端阅览
Cong ZENG, Xu CHEN, Juan HUA, et al. Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation[J]. Journal of Third Military Medical University, 2021, 43(21): 2302-2306.
DOI：

Cong ZENG, Xu CHEN, Juan HUA, et al. Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation[J]. Journal of Third Military Medical University, 2021, 43(21): 2302-2306. DOI： 10.16016/j.1000-5404.202108112.

摘要

目的

探讨祛铁治疗对异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation，allo-HSCT)后铁过载的恶性血液病患者造血功能的影响和安全性。

方法

回顾性分析本院2019年5月至2021年6月接受allo-HSCT后铁过载的恶性血液病患者38例的资料。根据是否使用祛铁治疗分成2组，其中治疗组21例(采用地拉罗司口服祛铁治疗)，对照组17例(未采用祛铁治疗)。观察两组患者的血红蛋白(hemoglobin，Hb)、血小板(platelet，PLT)、白细胞(white blood cell，WBC) 计数及血清铁蛋白(serum ferritin，SF)水平的变化，并观察用药期间的不良反应。

结果

在治疗后2、4、8周，与对照组相比，治疗组Hb、PLT水平较基线有明显升高(

＜0.05)；而WBC水平的变化与对照组差异无统计学意义(

＞0.05)。治疗组在4、8周SF水平较基线下降，与对照组相比差异有统计学意义[-867 (-1 918~477) μg/L

436 (-408~467) μg/L (

＜0.001)

-1 243 (-2 784~364) μg/L

541 (-674~578) μg/L (

＜0.001)

]

。治疗组患者均未发生严重的胃肠道症状及肝肾功能损害等不良反应。

结论

祛铁治疗能够有效改善异基因造血干细胞移植后铁过载的恶性血液病患者的造血功能，且安全性良好。

Abstract

Objective

To investigate the effect and safety of iron chelation therapy on hematopoiesis in hematological malignancy patients with iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods

The clinical data of 38 hematological malignancy patients who suffered from iron overload after allo-HSCT and were treated in our hospital from May 2019 to June 2021 were retrospectively reviewed and analyzed. According to receiving iron chelation or not

they were divided into treatment group (

=21

oral administration of deferasirox) and control group (

=17

no iron chelation). The changes of hemoglobin (Hb) level

platelet (PLT) count

white blood cell (WBC) count and serum ferritin (SF) level were compared between the 2 groups

and the adverse reactions during administration were observed as well.

Results

At 2

4 and 8 weeks after treatment

Hb level and PLT count in the treatment group were significantly improved from baseline as compared with the control group (

0.05)

but the WBC count showed no significant difference between the 2 groups (

0.05). SF levels in the treatment group was decreased from baseline at 4 and 8 weeks

significantly lower than those of the control group [-867 (-1 918~ 477)

436 (-408~467) μg/L

0.001;-1 243 (-2 784~364)

541 (-674~578) μg/L

0.001

]

. None of the patients in the treatment group developed serious gastrointestinal symptoms or severe damage to liver and

kidney functions.

Conclusion

Iron chelation therapy can effectively improve the hematopoiesis

with satisfactory safety

in the patients suffering from iron overload after allo-HSCT.

关键词

Keywords

references

XU L, CHEN H, CHEN J, et al . The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J ] . J Hematol Oncol, 2018, 11(1): 33. DOI: 10.1186/s13045-018-0564-x.

KHAN M A, BASHIR Q, CHAUDHRY Q U, et al . Review of haploidentical hematopoietic cell transplantation[J ] . J Glob Oncol, 2018, 4: 1-13. DOI: 10.1200/jgo.18.00130.

INAMOTO Y, LEE S J. Late effects of blood and marrow transplantation[J]. Haematologica, 2017, 102(4): 614-625. DOI: 10.3324/haematol.2016.150250.

KONTOGHIORGHES G J. How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation? [J]. Expert Rev Hematol, 2020, 13(4): 299-302. DOI: 10.1080/17474086.2020.1719359.

KONG Y, SONG Y, HU Y, et al . Increased reactive oxygen species and exhaus tion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants[J ] . Oncotarget, 2016, 7(21): 30892-30906. DOI: 10.18632/oncotarget.8810.

ISIDORI A, BORIN L, ELLI E, et al . Iron toxicity - Its effect on the bone marrow[J ] . Blood Rev, 2018, 32(6): 473-479. DOI: 10.1016/j.blre.2018.04.004.

ZHAO Y, GAO F, SHI J, et al . Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2019, 25(9): 1898-1907. DOI: 10.1016/j.bbmt.2019.05.036.

SUN Y Q, WANG Y, ZHANG X H, et al . Virus reactivation and low dose of CD34 + cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation[J ] . Ann Hematol, 2019, 98(8): 1877-1883. DOI: 10.1007/s00277-019-03715-w..

顾彩红, 李彩霞, 叶璐, 等. 祛铁治疗对伴铁过载骨髓增生异常综合征患者异基因造血干细胞移植的影响[J]. 中华血液学杂志, 2016, 37(3): 189-193. DOI: 10.3760/cma.j.issn.0253-2727.2016.03.003.

GU C H, LI C X, YE L, et al . Effect of iron removal therapy on allogeneic hematopoietic stem cell transplantation in patients with iron overload myelod ysplastic syndrome[J ] . Chin J Hematol, 2016, 37(3): 189-193. DOI: 10.3760/cma.j.issn.0253-2727.2016.03.003.

LOKE J, MALLADI R, MOSS P, et al . The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience[J ] . Br J Haematol, 2020, 188(1): 129-146. DOI: 10.1111/bjh.16355.

王佳丽, 韩明哲. 异基因造血干细胞移植后植入功能不良发生机制研究进展[J]. 中华血液学杂志, 2019, 40(9): 792-795. DOI: 10.3760/cma.j.issn.0253-2727.2019.09.021.

WANG J L, HAN M Z. The pathogenesis of poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Chin J Hematol, 2019, 40(9): 792-795. DOI: 10.3760/cma.j.issn.0253-2727.2019.09.021.

SONG Y, ZHAO H Y, LYU Z S, et al . Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2018, 24(10): 1981-1989. DOI: 10.1016/j.bbmt.2018.06.021.

GHOBADI A, FIALA M A, RAMSINGH G, et al . Fresh or cryopreserved CD34 + -selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation[J ] . Biol Blood Marrow Transplant, 2017, 23(7): 1072-1077.DOI: 10.1016/j.bbmt.2017.03.019..

ATILLA E, TOPRAK S K, DEMIRER T. Current review of iron overload and related complications in hematopoietic stem cell transplantation[J]. Turk J Haematol, 2017, 34(1): 1-9. DOI: 10.4274/tjh.2016.0450.

MEYER S C, O'MEARA A, BUSER A S, et al . Prognosticimpact of posttransplantation iron overload after allogeneic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2013, 19(3): 440-444. DOI: 10.1016/j.bbmt.2012.10.012.

LEITCH H A, GATTERMANN N. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions[J]. Crit Rev Oncol Hematol, 2019, 141: 54-72. DOI: 10.1016/j.critrevonc.2019.06.002.

QUARTA A, SGHERZA N, PASANISI A, et al . Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusion-dependent-thalassemia[J ] . Br J Haematol, 2020, 189(2): e60-e63. DOI: 10.1111/bjh.16468.

VIPRAKASIT V, AJLAN A, AYDINOK Y, et al . MRI for the diagn osis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: an algorithm to guide clinical use when availability is limited[J ] . Am J Hematol, 2018, 93(6): E135-E137. DOI: 10.1002/ajh.25075.

ZHANG Y, ZHAI W, ZHAO M, et al . Effects of iron overload on the bone marrow microenvironment in mice[J ] . PLoS ONE, 2015, 10(3): e0120219. DOI: 10.1371/journal.pone.0120219.

OKABE H, SUZUKI T, UEHARA E, et al . The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice [J ] . Eur J Haematol, 2014, 93(2): 118-128. DOI: 10.1111/ejh.12309.

ZHANG X, SHI Y, HUANG Y, et al . Serum ferritin is a different predictor from transfusion history for allogeneic transplantation outcome in patients with severe aplastic Anemia[J ] . Hematology, 2018, 23(5): 291-298. DOI:10.1080/10245332.2017.1390929.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A combined strategy of surface markers for sorting immune cell subsets in patients with chronic graft-versus-host disease

Risk factors for late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: analysis of 227 cases

Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease

Related Author

Yuxuan DU

Ping WANG

Xiaojun GE

Xiaoqi WANG

Tao HONG

Weihao WANG

Yundi HE

Ruihao HUANG

Related Institution

Department of Clinical Laboratory, the Second Affiliated Hospital of Zunyi Medical University

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Hematology, the First Affiliated Hospital of Chongqing Medical University

Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)

⁰